跳至主要内容
临床试验/IRCT20190904044697N6
IRCT20190904044697N6招募中未知

Targeted drug delivery using polar or charged drugs by opposite electrostatic charge, in breast cancer clinical trial

Iran Nano Fund0 个研究点目标入组 40 人开始时间: 待定最近更新:
适应症

试验速览

阶段
未知
状态
招募中
发起方
入组人数
40

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
no limit 至 no limit(—)
性别
All

入选标准

  • All breast cancer type patients, with different stages, by distinguished tissue biopsy to normal one which confirmed the tumor existence.
  • Pathological or radiological evidence of tumor existence.
  • All breast cancer patients become a chemotherapy candidate in neoadjuvant, adjutant? and post-operative circumstance.
  • Patients who are indicated for administration polar water-soluble or charged chemotherapy drugs such as cisplatin, carboplatib, cyclophosphamide, doxorubicin

排除标准

  • Patients who do not have appropriate general condition and need intensive care.
  • Patients who have no assessable tumor for treatment evaluation.
  • Coagulation disorders (INR>1.5)
  • Thrombocytopenia (Platelets<150000)
  • Anemia (Hemoglobin<12)
  • Acute Infection
  • Patients with pacemaker or any types of cardiac arrhythmia
  • Abnormal biochemistry or electrolyte of the serum.
  • Neutropenia (neutrophil<1500)
  • Patients who are not receiving polar or charged chemotherapy drugs

研究者

发起方
Iran Nano Fund

相似试验

Targeted polar or charged drug delivery, using... | 临床试验